Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies.

Amado J Zurita Ryon P Graf Guillermo Villacampa Kira Raskina Ethan S SokolDexter JinEmmanuel S AntonarakisGerald LiRichard S P HuangIrene Casanova-SalasAna Vivancos Joan Carles Jeffery S Ross Alexa B Schrock Geoffrey R Oxnard Joaquin Mateo

Published in: JCO precision oncology (2022)

Prevalence of HRR-gene aberrations remains stable along mPC progression, supporting the use of diagnostic biopsies to guide poly (ADP-ribose) polymerase inhibitor treatment in metastatic castration-resistant prostate cancer. gLOH scores increase with emerging resistance to hormonal therapies, independently of individual HRR gene mutations.

Keyphrases

genome wide
copy number
prostate cancer
squamous cell carcinoma
small cell lung cancer
dna methylation
radical prostatectomy
risk factors
polycystic ovary syndrome
gene expression
skeletal muscle
ultrasound guided